MedWatch

Biotech company aims for sale before next development phase

On an early experimental stage, the Danish biotech company Rhovacs has developed a cancer vaccine that successfully mobilizes the patient’s own immune system against cancer. The company hopes that the positive data will result in a sale of the firm.

So far, seven out of eight patients have responded to the cancer vaccine candidate RV001in a clinical phase I/II trial.

This is good news for the Danish biotech company Rhovac, listed on the small Swedish stock market Aktietorget.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier